Simultaneously occurring chronic myelogenous leukemia and gastrointestinal stromal tumors treated with imatinib

Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037

Miettinen M, Majidi M, Lasota J (2002) Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 38(Suppl 5):S39–51

Demetri GD (2002) Identification and treatment of chemo-resistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer 38(Suppl 5):S52–S59

Joensuu H, Fletcher C, Dimitrijevic S et al (2002) Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3:655–664

Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813–3825

Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480

Kantarjian H, Talpaz M, O’Brien S et al (2004) High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103:2873–2878

Debiec-Rychter M, Dumez H, Judson I et al (2004) Use of c-KIT/PDGFRα mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40:689–695

Singer S, Rubin BP, Lux ML et al (2002) Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20:3898–3905

Kim TW, Lee H, Kang YK et al (2004) Prognostic significance of c-KIT mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 10:3076–3081